A subsequent phase I clinical trial with soluble TACI in RA patients showed a decrease in levels of rheumatoid factor and antibodies against citrullinated proteins in treated patients [20,21], indicating promising perspectives for such a therapeutic approach. The gene discussed is TNFRSF13B; the disease is rheumatoid arthritis.